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A B S T R A C T
Primary cutaneus apocrine carcinoma is a rare malignancy with about 50 cases reported in the literature. Axilla is
the most common site of occurrence, but locations like scalp, anogenital region, ear canal, chest, wrist, finger and eyelid
have been described. The neoplasm presents itself as an asymptomatic, slow-growing, solid or cystic mass that varies in
color. Most patients have a history of a long-standing neoplasm before the diagnosis is made. The disease is considered to
have an indolent clinical course with favorable outcome although more than half of reported patients had regional
lymph node metastases at the time of diagnosis. Systemic dissemination to lung, bones, liver and brain is extremely rare
with only 14 cases documented in the literature. Wide surgical excision with lymph node dissection upon confirmation of
the lymph node metastases remains the only curable treatment. Care and management of the disseminated disease is still
challenging. We report a case of a 65-year-old woman with a very aggressive apocrine carcinoma of the scalp prone to lo-
cal recurrence and distant metastases to lung and bones.
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Introduction
Apocrine carcinoma of the skin is an extremely rare
malignant sweat gland neoplasm with about 50 cases re-
ported in the literature1,2 and no apparent preference to-
ward gender, race or ethnicity. It is predominant in
adults, age 50–70 years and affects body regions with
high apocrine gland density. Axilla is the most common
site, and other rare locations are the scalp, anogenital re-
gion, ear canal, chest, wrist, finger and eyelid3–6.
Most patients usually present with an asymptomatic,
slow growing, single or multiple, cutaneous or subcuta-
neous masses, which can be solid or cystic and vary in
color from red to purple. It is often not diagnosed clini-
cally since there are no distinguishable characteristics to
raise suspicion. Time from the presentation of the skin
lesion to the final diagnosis is prolonged, with most pa-
tients having a history of less than 1 year; still intervals
of up to 30 years have been noted4,6,7.
Pathohistologically, apocrine carcinoma has the ap-
pearance of adenocarcinoma with specific characteristics
that include decapitation secretion, periodic acid-Schiff-
-positive diastase resistant material in the cells or in the
lumen and positive immunostaining for gross cystic dis-
ease fluid protein1,3–6. One report suggests tumor associ-
ated glycoprotein-72 (TAG-72) as a possible serum tumor
marker for apocrine carcinoma, since its levels were ele-
vated preoperatively and returned to normal levels after
extirpation2. These tumors display different architec-
tural glandular patterns including papillary, tubular, so-
lid or complex patterns. The female breast is develop-
mentally and morphologically a modified apocrine gland.
Breast carcinoma with apocrine features is pathohisto-
logically very much alike cutaneous apocrine carcinoma
and it must be excluded as a possible diagnosis with a
clinical work-up2,4,6.
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Apocrine malignancies are initially only locally inva-
sive but an early onset of regional lymph node metasta-
ses was also described. More than half of the reported
patients with apocrine carcinoma had lymph node meta-
stases at the time of diagnosis6. Systemic dissemination
to the liver, lung, bones and brain is rare. Chamberlain et
al. reported 10 cases, but additional reports that have
been published since raise the number to only 14 cases
of disseminated metastatic apocrine carcinoma in to-
tal1,6,8–10. First treatment option is a wide, local surgical
excision with clearance of affected lymph nodes. The use
of adjuvant chemotherapy and radiotherapy has not been
fully determi- ned6,8–11. Prognostic factors are difficult to
establish due to low prevalence of the disease. Tumor
size and site, lymphovascular and perineural invasion,
histological type, degree of differentiation and resection
margins are noted to have prognostic significance4,6.
Most cases are reported to be indolent in their clinical
course and rarely fatal.
Here, we report a case of a very aggressive apocrine
carcinoma of the scalp prone to local recurrence with dis-
tant metastases to lung and bones.
Case Report
A 65-year-old woman presented with a 3 year history
of a left scalp mass and enlarged nodes on the left side of
the neck. Patient’s past medical history included type 2
diabetes mellitus and arterial hypertension that were
controlled by medication.
Physical examination showed a 4-cm-wide nummular,
indurated, pink, painless skin mass of left parietal region
with enlarged lymph nodes in II and V left cervical re-
gion. Excision biopsy and pathohistological examination
reported carcinoma of apocrine origin. Ultrasound-gui-
ded fine-needle aspiration biopsy of the enlarged cervical
lymph nodes confirmed metastasis from the same neo-
plasm. Other laboratory and radiographic findings were
normal.
Tumorous mass of the scalp was radically excised
with approximately 2 cm free surgical margins, skin de-
fect was covered by skin grafting and extended radical
neck dissection left was performed. Histology findings of
resected scalp specimen revealed a poorly differentiated
apocrine carcinoma. Epidermis was intact and the neo-
plasm was centered in the dermis with papillary exten-
sions invading subcutaneous tissue. The tumor had
mixed solid-cystic pattern but predominantly solid archi-
tecture. Malignant cells had medium sized nuclei and
abundant eosinophilic cytoplasm (Figure 1). Vascular in-
vasion was present. Surgical margins were negative.
Immunohistochemical staining showed tumorous cells
positive for gross cystic disease fluid protein (GCDFP+),
cytokeratin7 (CK7+) and epithelial membrane antigen
(EMA+), and negative for S100 protein, cytokeratin20
(CK20) and carcinoembryonic antigen (CEA). The origi-
nal scalp tumor specimen that had been obtained at the
first excision biopsy was examined and compared. Find-
ings were identical and the diagnosis was confirmed.
Eight out of 30 isolated nodes were metastatic. Patient
was referred to an oncologist. An extensive work-up re-
vealed no evidence of visceral malignancy and apocrine
breast cancer was excluded with breast ultrasound,
mammography and breast magnetic resonance imaging.
The patient was given an adjuvant chemotherapy, 4 cy-
cles of cisplatin and 5-fluorouracil preceded with exter-
nal beam electron radiotherapy to the left scalp (total
dose of 50 Gy) and cobalt radiotherapy to the neck (two
opposing fields, total dose of 60 Gy).
The patient was well and asymptomatic for 10 months,
when the local recurrence appeared in the left retro-
auricular region (Figure 2). The ultrasound examination
of the neck with fine-needle aspiration biopsy revealed
contralateral cervical lymph node metastases. The pa-
tient underwent tumor re-excision, reconstruction of the
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Fig. 1. Photomicrograph of the resected original scalp mass. Le-
sion is centered in the dermis with papillary extensions invading
subcutaneous tissue and has predominantly solid architecture.
Hematoxylin and eosin staining shows poorly differentiated
apocrine carcinoma.
Fig. 2. Local recurrence of the tumor in the left retroauricular
region. Original site of tumor covered with skin grafting (black
arrow).
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defect with a rotational lobe and selective neck dissection
in region I,II,III right. Histology was the same as before,
with positive surgical margins and involvement of 8 out
of 23 dissected lymph nodes with perinodal infiltration.
After 2 months a recidive tumor appeared and anterior
cervical nodes were positive. The patient was taken up
for another tumor re-excision with selective neck dissec-
tion. Ultrasound examination also revealed an enlarged
hypoechoic node in the left axilla following its evacua-
tion. Pathohistological examination confirmed a meta-
static apocrine carcinoma. The patient had no evidence
of visceral or pulmonal metastases. Second line of chemo-
therapy in form of paclitaxel and carboplatin every 21
days was admitted. The patient was without symptoms
and local recurrence for 4 months. Positron emission to-
mography-computed tomography (PET-CT) scan revealed
abnormal uptake at nodular lesion in the left parieto-oc-
cipital, retromandibular and parotid region. Abnormal
uptake was also found in the intra-abdominal lymph
nodes in the region of porta hepatis and hepatoduodenal
ligament. Multiple lung metastases, osteolytic lesion of
the left iliac bone, right shoulder and L5 vertebrae were
also noted by the PET scan. This led to withdrawal of the
chemotherapy treatment and administration of iban-
dronic acid. Locoregional cutaneous metastases were in-
filtrating the skin on the whole left side of the neck and
upper pectoral region (Figure 3). The patient clinical
condition was gradually deteriorating in a sense of short-
ness of breath and fatigue. Progression of the lung meta-
stases to pulmonary carcinomatous lymphangiosis were
revealed by chest X-ray examination. Three years after
the initial diagnosis at the age of 68 the patient pre-
sented with confusion, disorientation and drowsiness.
However, brain metastases were not observed by the
computed tomography (CT) scan of the brain. The pa-
tient was treated with antiedematous and supportive
therapy but died due to respiratory failure caused by pul-
monary lymphangiosis.
Discussion
We report a very rare case of a recurrent apocrine car-
cinoma of the scalp with a very aggressive clinical course.
The tumor was undifferentiated and prone to local recur-
rence, lymphatic and hematogenous dissemination. Ac-
cording to the literature, disseminated metastatic apo-
crine carcinomas are extremely rare and only 14 cases
have been reported to date1,6,8–10.
Our patient was treated with repeated local excisions
and dissections of involved lymph node regions at the be-
ginning of the disease. The only recommended and cur-
able treatment for localized apocrine carcinoma is wide
surgical excision with dissection of the lymph nodes, if
lymphatic spread has been proven. Some authors advise
prophylactic regional lymph node dissection particularly
in cases of recurrent local lesions after wide excision or
with poorly differentiated tumors while others state that
prophylactic lymph node dissection does not inhance sur-
vival rate8,9.
Care and management of the disseminated disease re-
mains challenge. Each following case report outlines di-
verse responses to multiple applied chemotherapy drugs.
Tlemcani et al. report response to chemotherapy durable
for 16 months in the case of a metastatic apocrine carci-
noma of the scalp with multiple lung and bone metasta-
ses treated with paclitaxel and carboplatin every 21 days
combined with palliative radiotherapy to the bone le-
sions8. Another report depicts a patient with a metastatic
apocrine carcinoma of the scalp who received several reg-
imens of chemotherapy that included 4 courses of adria-
mycin, etoposide and docetaxel periodically which stabi-
lized the disease for approximately 2 years when it final-
ly progressed to the brain1. Gallerani et al. report a case
of a metastatic axillary apocrine carcinoma that evolved
during treatment with cisplatin and cetuximab10. Kumar
et al. portray a case of an apocrine carcinoma of the eye-
lid with an optimal response to cisplatinum, adriamycin
and cyclophosphamide that controlled the disease for
about 2 years5. Adjuvant chemotherapy in form of 5-fluo-
rouracil and cisplatin combined with adjuvant radiation
controlled the apocrine carcinoma of the arm for 6 months
until it worsened with lung metastases9. Evidently, meta-
static apocrine carcinoma generally has a weak response
to chemotherapy. Nonetheless, patients with dissemi-
nated disease should be treated with any applicable che-
motherapy regime reported in the literature by now.
Reports on the efficiency of radiotherapy vary: some
impose radioresistance and others recommend adjuvant
radiation in cases with advanced local and regional meta-
stases. Chamberlain et al. suggested local adjuvant radia-
tion for large tumors (> 5 cm), positive surgical margins
or poorly differentiated lesions with lymphovascular in-
vasion and adjuvant radiation to the affected regional
lymph nodes in the case of extranodal extension or in-
volvement of more than 4 lymph nodes6. Deficient litera-
ture offers no appropriate radiation treatment plan con-
taining schedule or dose.
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Fig. 3. Locoregional cutaneous metastases infiltrating the skin
on the whole left side of the neck and upper pectoral region.
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Our patient recieved adjuvant radiotherapy to the left
scalp and neck, followed by adjuvant chemotherapy in
form of 4 cycles of cisplatin and 5-fluorouracil. Regard-
less of both surgical and non-surgical therapeutic mea-
sures, the disease was controlled only for 10 months
when local recurrence appeared. According to the litera-
ture, a long term remission is achievable by surgery
alone despite the local recurrences and regional lymph
node metastases that may occur years after the first op-
eration. Some authors reported a 28% 5-year recurrence
rate5,6. As stated in the literature, prolonged remission of
the disseminated disease is achievable, however, the dis-
ease is without exception fatal at this stage. We believe
that repeated local excisions and dissections of affected
lymph node regions, accompanied by second line of che-
motherapy (paclitaxel and carboplatin) delayed the pro-
gression of the disease briefly before it disseminated to
distant lymph nodes, lung, bones and probably brain.
Pulmonary metastases showed considerably rapid pro-
gression and finally were the cause of our patient demise.
Clinical trials and investigations in order to attain
specific guidelines regarding adjuvant radiotherapy and
chemotherapy are almost impossible to conduct due to
the rareness of the disease and may never be available.
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APOKRINI KARCINOM KO@E GLAVE AGRESIVNOG KLINI^KOG TIJEKA – PRIKAZ SLU^AJA
I PREGLED LITERATURE
S A @ E T A K
Primarni ko`ni karcinom podrijetla apokrinih `lijezda je rijetka maligna bolest sa oko 50 slu~ajeva prikazanih u
literaturi. Naj~e{}e zahva}a podru~je aksile ali opisani su i na ko`i glave, anogenitalne regije, vanjskog zvukovoda,
prsi{ta, {ake, prstiju te vije|a. Neoplazma se prezentira kao asimptomatska, spororastu}a, ~vrsta ili cisti~na tumorska
masa s varijacijama u boji. Ve}ina pacijenata ima anamnezu o dugotrajnom postojanju neoplazme prije postavljanja
dijagnoze. Smatra se bole{}u indolentnog klini~kog tijeka sa o~ekivanim povoljnim ishodom iako vi{e od polovice paci-
jenata u trenutku postavljanja dijagnoze ima zahva}ene regionalne limfne ~vorove. Dokumentirano je samo 14 slu~a-
jeva sistemske diseminacije bolesti s metastazama u plu}a, kosti, jetru i mozak. [iroka resekcija tumora sa disekcijom
zahva}enh limfnih ~vorova je jedina djelotvorna metoda lije~enja. Lije~enje metastatske bolesti i dalje predstavlja iza-
zov. Prikazujemo slu~aj 65-godi{nje `ene sa izrazito agresivnim apokrinim karcinomom ko`e glave, sklonim lokalnim
recidivima, udaljenim metastazama u plu}a i kosti.
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